Agenus

Today we announced that Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA to discuss our botensilimab/balstilimab therapy for relapsed or refractory metastatic colorectal cancer. Learn more: https://bit.ly/3yqGtCY

“With this infusion of capital, we are poised to accelerate the development of our lead therapeutic combination regimen, botensilimab/balstilimab, which we expect to make a significant impact in the treatment of MSS colorectal cancer. This initiative brings us closer to our goal of dramatically improving cancer treatment for patients who are often left with limited or no options.” Chairman & CEO Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals.

Yesterday, we announced our Q1 earnings report and corporate update, inclusive of our strategic partnership with Ligand Pharmaceuticals - validating our advancements in investigational immunotherapy botensilimab/balstilimab programs, deep partnership pipeline, and commercial readiness. Read more about our progress and strengthened financial position here: https://bit.ly/4b7uwjH

Today we announced a royalty financing agreement with Ligand Pharmaceuticals. This collaboration enables Agenus to accelerate our efforts to bring botensilimab/balstilimab to patients. Learn more here: https://bit.ly/3WsFFXV

May 1st marks the start of Cancer Research Month. Join us as we recognize the significant strides in cancer care and raise awareness to support millions worldwide affected by this disease. We extend our gratitude to the tireless efforts of our scientists and the entire research community driving progress every day. 🔬 #CancerResearchMonth #CancerAwareness #CancerResearch #Immunotherapy

Mark your calendars! We have been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) #ASCO2024 Annual Meeting. Join us on June 1st as we present a sub-analysis of the MSS colorectal cancer cohort from our Phase 1b study of botensilimab and balstilimab.   See the details here: https://bit.ly/44eR53n

Today we announced an agreement with InvivoGen for the supply of our STIMULON cultured plant cell (cpc) QS-21 adjuvant. Under this collaboration, SaponiQx will manufacture cpcQS-21 for InvivoGen to sell to labs, academic institutions, and industry partners worldwide.   Read more about our progress toward advancing a sustainable supply of this key adjuvant: https://lnkd.in/eiFAcsWe   #QS21 #VaccineDevelopment #Adjuvants

Today we announced updated Phase 1 data and progress on our investigational botensilimab/balstilimab combination in patients with metastatic MSS colorectal cancer. Get the latest: https://bit.ly/3xz17QH #ColorectalCancer #botensilimab #immunotherapy #ClinicalTrials

We’ve been energized and inspired by our time at #AACR2024.   Yesterday our Vice President of Research, Dhan Chand, presented preclinical data on the activity of BMS-986442, Bristol Myers Squibb’s bispecific TIGIT program that was licensed from Agenus in 2021 (formerly AGEN1777). View the presentation at: https://lnkd.in/eqzP6-JF   #Immunotherapy #CancerResearch #TIGIT

As Colorectal Cancer Awareness Month comes to a close, we reflect on the importance of raising awareness and supporting those affected by this disease. Throughout March, members of the Agenus team proudly wore blue to show their support and commitment to making a difference for the CRC community.   Beyond the month of March, Agenus will continue on our mission to harness the power of the immune system to bring immunotherapies to patients and work towards a future free from colorectal cancer.   #ColorectalCancerAwarenessMonth #CancerCare #Immunotherapy